Confidential mandate
Enterprise Stress Testing Production Director
Planned Hiring / New
Enterprise Stress Testing Production Director mandate in Kuala Lumpur, Malaysia
Confidential Enterprise Stress Testing Production Director in Kuala Lumpur, Malaysia, reporting to the Chief Risk Officer. Interim Quantitative Analysis appointment at Director level, a 12-month mandate horizon; five days a week.
The mandate
The Interim Director will stabilise enterprise stress testing from approved narrative through quantitative translation, model execution, aggregation, challenge and executive result. The twelve-month horizon covers one complete major cycle and a successor-led repeat. It does not own capital or liquidity actions, risk appetite, regulatory representation or long-term platform replacement.
During the initial month, the Director will observe the current cycle, trace selected variables and reconcile model outputs through aggregation. Authority includes setting the production command rhythm, rejecting unsupported scenario translations, requiring reruns, assigning defect ownership and escalating unreliable results. Methodology, scenario approval and management decisions retain their established authorities.
The recovery will distinguish narrative ambiguity, translation inconsistency, source-data weakness, model limitation, implementation defect, aggregation error and overlay judgment. Cross-risk feedback and management actions must be represented once, with timing and feasibility explicit. Every late intervention will be classified so the next cycle corrects causes rather than normalising heroics.
The Director will also maintain run-to-run evidence for approvals and reruns, ensuring that a late correction cannot silently overwrite the version already reviewed by another governance layer.
By month five, an authoritative dependency map, scenario dictionary, version control and result bridge should be operating. The first full cycle will prove them. The nominated successor then commands a second exercise containing seeded variable-mapping, model-version and management-action conflicts, and presents residual uncertainty to the acceptance committee.
Handover is accepted only when the Chief Risk Officer approves artifacts and the successor successfully completes that end-to-end exercise. Broader methodology rebuild, strategic response, formal assurance, permanent staffing and technology implementation are excluded. Extension cannot be used merely because stakeholders request additional scenarios.
What you will own
- Establish a single production map connecting narrative, variables, data, models, overlays, aggregation and executive reporting.
- Govern scenario translation through definitions, units, horizons, paths, ownership and cross-variable consistency.
- Control model, data and code versions with reproducible run evidence and authorised change cut-offs.
- Reconcile results across models and periods, decomposing scenario, exposure, method, overlay and implementation effects.
- Prevent duplicate management actions and cross-risk feedback through explicit ownership and feasibility tests.
- Complete one stable primary cycle and a successor-led repeat containing designed exceptions.
- Record limitations and residual uncertainty so governance can distinguish result from unsupported precision.
- Maintain scope boundaries around strategy, assurance, permanent organisation and platform build.
Candidate qualifications
- Demonstrate interim command of enterprise stress production involving several quantitative domains.
- Describe a scenario-translation inconsistency that produced materially misleading aggregate output.
- Show how you detected double-counted feedback or management action across models.
- Evidence version and rerun governance under an immovable submission calendar.
- Provide movement decomposition that turned an unexplained result into accountable corrective actions.
- Explain how you kept production recovery separate from methodology redevelopment and strategy.
- Show a successor running an end-to-end cycle with seeded defects before your exit.
Working terms and boundaries
- The twelve-month appointment is five days weekly and includes primary production, repeat proof and handover.
- Day rates cover on-site command and normal peak-cycle intensity; exceptional travel needs approval.
- The Director controls production evidence but not scenario approval, appetite, strategic action or regulatory representation.
- Platform replacement, broad redevelopment, formal assurance and permanent team design are excluded.
- A six-week extension requires incomplete successor-led acceptance against documented criteria.
Application
Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.
There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 6 October 2026. Mandate reference QNT-INT-2026-KUL-26.
More seats like this one
This mandate is confidential. The client is named only under a mutual NDA, and your own record is never listed, sold or shown to a company under your name until you release it for this specific mandate.